Parkinson's Progression Markers Initiative
Names
More detailed information about this field from each metasource.
Parkinson's Progression Markers Initiative
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
PPMI
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Names
More detailed information about this field from each metasource.
Parkinson's Progression Markers Initiative
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
PPMI
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Names
More detailed information about this field from each metasource.
Parkinson's Progression Markers Initiative
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
PPMI
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
PPMI is an observational clinical study to verify progression markers in Parkinson’s disease. The study is designed to establish a comprehensive set of clinical, imaging and biosample data that will be used to define biomarkers of PD progression. Once these biomarkers are defined, they can be used in therapeutic studies. The clinical, imaging and biologic data are accessible to researchers in real time through the website.
Description
More detailed information about this field from each metasource.
PPMI is an observational clinical study to verify progression markers in Parkinson’s disease. The study is designed to establish a comprehensive set of clinical, imaging and biosample data that will be used to define biomarkers of PD progression. Once these biomarkers are defined, they can be used in therapeutic studies. The clinical, imaging and biologic data are accessible to researchers in real time through the website.
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Webpage:
http://www.ppmi-info.orgWebpage
More detailed information about this field from each metasource.
http://www.ppmi-info.org
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Licence:
Name: PPMI Data Use AgreementLicence name
More detailed information about this field from each metasource.
PPMI Data Use Agreement
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Licence URL
More detailed information about this field from each metasource.
http://www.ppmi-info.org/documents/ppmi-data-use-agreement.pdf
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Publications:
Publications
More detailed information about this field from each metasource.
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
PMID: 26268663
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
http://dx.doi.org/10.1016/j.pneurobio.2011.09.005
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Publications
More detailed information about this field from each metasource.
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
PMID: 26268663
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
http://dx.doi.org/10.1016/j.pneurobio.2011.09.005
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
-
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
PubMed citations: 30.
30 articles citing: Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
SNCA rs3910105 Is Associated With Development of Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease. PMID:35310107
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. PMID:34984729
Development and Validation of a Prognostic Model for Cognitive Impairment in Parkinson's Disease With REM Sleep Behavior Disorder. PMID:34322014
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource. PMID:33960523
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. PMID:33881531
Polygenic Score Models for Alzheimer's Disease: From Research to Clinical Applications. PMID:33854414
Common X-Chromosome Variants Are Associated with Parkinson Disease Risk. PMID:33583074
Network Protein Interaction in Parkinson's Disease and Periodontitis Interplay: A Preliminary Bioinformatic Analysis. PMID:33238395
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. PMID:32888397
Excess of singleton loss-of-function variants in Parkinson's disease contributes to genetic risk. PMID:32054687
Parkinson's disease prognostic scores for progression of cognitive decline. PMID:31767922
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease. PMID:31361367
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. PMID:31315608
TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. PMID:30973966
An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele. PMID:30826425
Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts. PMID:30824863
Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease. PMID:30742647
A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease. PMID:30484896
Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort. PMID:30480086
No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease. PMID:30340792
A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease. PMID:30146727
Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. PMID:30089514
Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. PMID:29141588
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. PMID:29030452
Predicting progression in patients with Parkinson's disease. PMID:28958800
Latent Cognitive Phenotypes in De Novo Parkinson's Disease: A Person-Centered Approach. PMID:28651678
NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. PMID:28602509
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PMID:28520803
Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations. PMID:27494614
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. PMID:27113479 - http://dx.doi.org/10.1016/j.pneurobio.2011.09.005
Tags:
Tags
More detailed information about this field from each metasource.
biomarker
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
disease
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
imaging
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
medical imaging
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
parkinson's disease
metasource: Fairsharing.org
version: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
Tags
More detailed information about this field from each metasource.
biomarker
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
disease
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
imaging
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
medical imaging
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
parkinson's disease
metasource: Fairsharing.orgversion: FAIRsharing.org: PPMI; Parkinson's Progression Markers Initiative; DOI: https://doi.org/10.25504/FAIRsharing.tamp4p; Last edited: Jan. 8, 2019, 1:21 p.m.; Last accessed: Jan 03 2022 7:09 p.m.
biomarker disease imaging medical imaging parkinson's disease
Need help integrating and/or managing biomedical data?